The fate of riboflavin in the mammal.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Christensen.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The need to develop methods for serological sample surveys has increased during recent years. The article describes the methods of sampling and blood collecting employed in a serological survey which was conducted in three different areas of Kenya.The purpose of the survey was primarily to gather information about the age-specific prevalence of various infections which were thought to pose public health problems in the country. An attempt was also made to identify environmental factors which might be associated with variation in the prevalence of the different infections. This was done by collecting data about such factors at the same time as the serological specimens were obtained in the selected survey groups.The experience gained during the field work showed that it is possible to achieve a high coverage of bleeding (80%) in randomly selected population groups living in rural Kenya when proper incentives are given to the examines. Venous blood could be obtained from subjects under field conditions down to the age of 2 years; from the babies only capillary blood could be obtained.
Arbovirus infections are of public health interest in East Africa, where a very widespread epidemic of o'nyong-nyong fever was reported in 1959-60 and where the threat of yellow fever, present in neighbouring areas such as Ethiopia, remains. Sera collected in a serological survey in Kenya were therefore tested for antibodies against 3 group-A arboviruses (chikungunya, o'nyong-nyong and Sindbis), 6 group-B arboviruses (Zika, yellow fever, West Nile, Banzi, Wesselsbron and dengue 1), and Bunyamwera virus. The sera were examined mainly by the haemagglutination-inhibition test but a small proportion were also subjected to virus neutralization tests.The results showed that the prevalence of arbovirus tnfection varies markedly from area to area in Kenya. All types of arbovirus infections were more frequent on the coast than on the dry plateau around Kitui and the Lake Victoria area, The only exceptions were o'nyong-nyong and chikungunya, which were found to be just as prevalent on the coast as in Nyanza, where an epidemic was reported in 1959-60. Yellow fever antibodies were found to be present in about half of the people living on the coast but practically absent from the other two areas. It was concluded that the yellow fever antibodies in the coastal area must be due either to vaccination or to cross-reactions with other group-B arboviruses.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Ceftibuten is an orally active third generation cephalosporin with increased potency against members of the Enterobacteriaceae. In this study, 74 women with acute uncomplicated urinary tract infection (UTI) were enrolled in an open study to evaluate the safety and efficacy of this new antibiotic. Patients were treated with 400 mg ceftibuten once daily for seven days and followed for four to six weeks after cessation of therapy. All pathogens were eradicated during treatment, including five coagulase-negative staphylococci that were resistant to ceftibuten. At five to nine days posttreatment, 93% of patients were cured. Of the five recurrent infections, four patients had a relapse and one had a reinfection. By four to six weeks posttreatment, five additional patients had recurrent infections. The overall cure rate was 85% in this study. Most ceftibuten-associated adverse effects were mild and involved the gastrointestinal tract. Diarrhea was the most commonly reported side effect. Of the eight (11%) patients who developed diarrhea, three had a positive latex agglutination test for Clostridium difficile. The diarrhea resolved in all patients without sequelae. Ceftibuten was effective and generally safe in the treatment of women with acute uncomplicated UTI. The high incidence of diarrhea observed in this study is a concern.